Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 2MD: Phase IIb data

    Deltanoid Pharmaceuticals Inc., Madison, Wis. Product: 2MD, DP001 Business: Endocrine/Metabolic Molecular target: Vitamin D receptor (VDR) Description: Vitamin D analog Indication: Treat secondary hyperparathyroidism (…

    Published on 11/24/2014
  • Actimab-A: Interim Phase I/II data

    Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.ZZZ. Product: Actimab-A Business: Cancer Molecular target: CD33 Description: Actinium-225 attached to the anti-CD33 mAb lintuzumab (HuM195) Indication: Treat …

    Published on 11/24/2014
  • AG-120: Phase I data

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-120 Business: Cancer Molecular target: Isocitrate dehydrogenase 1 (IDH1) Description: Inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) …

    Published on 11/24/2014
  • Aloxi palonosetron: Phase III data

    Helsinn Healthcare S.A., Lugano, Switzerland Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Aloxi palonosetron Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Selective serotonin…

    Published on 11/24/2014
  • BIND-014: Additional Phase II data

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Product: BIND-014 Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Polymeric nanoparticle containing …

    Published on 11/24/2014
  • BTI-320: Phase IIb data

    Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320) Business: Endocrine/Metabolic Molecular target: NA Description: Chewable polysaccharide that inhibits alpha glucosidase …

    Published on 11/24/2014
  • Cometriq cabozantinib: Phase II data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); c-Met …

    Published on 11/24/2014
  • Galactoarabino-rhamnogalacturonate: Additional Phase I data

    Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga. Product: Galactoarabino-rhamnogalacturonate (GR-MD-02) Business: Hepatic Molecular target: Galectin-3 (LGALS3); Galectin-1 (LGALS1) Description: Galectin-3 (LGALS3…

    Published on 11/24/2014
  • JVS-100: Phase IIa data

    Juventas Therapeutics Inc., Cleveland, Ohio Product: JVS-100 Business: Cardiovascular Molecular target: Stromal cell-derived factor-1 Description: Non-viral DNA plasmid encoding stromal cell-derived factor-1 Indication:…

    Published on 11/24/2014
  • Mekinist trametinib: Additional Phase III data

    Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mekinist trametinib (GSK1120212) Business: Cancer Molecular target: MAP kinase kinase 1 (MAP2K1) (MEK1); MAP …

    Published on 11/24/2014
  • Metadoxine ER: Additional Phase III data

    Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 11/24/2014
  • NBS-10: Preliminary Phase II data

    NeoStem Inc. (NASDAQ:NBS), New York, N.ZZZ. Product: NBS-10, AMR-001 Business: Cardiovascular Molecular target: CD34; CXC chemokine receptor 4 (CXCR4) (NPY3R) Description: Autologous bone marrow-derived stem cells …

    Published on 11/24/2014
  • NVR-1221: Phase Ia data

    Novira Therapeutics Inc., Radnor, Pa. Product: NVR-1221, NVR 3-778 Business: Infectious Molecular target: NA Description: Oral small molecule inhibitor of the HBV core or capsid protein Indication: Treat chronic HBV …

    Published on 11/24/2014
  • Opdivo nivolumab: Additional Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.ZZZ. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 11/24/2014
  • Relamorelin: Phase IIa data

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Rhythm Pharmaceuticals Inc., Boston, Mass. Product: Relamorelin (RM-131) (formerly BIM 28131) Business: Gastrointestinal Molecular target: Ghrelin …

    Published on 11/24/2014
  • Rindopepimut: Additional Phase II data

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Rindopepimut (CDX-110) (formerly PF-04948568) Business: Cancer Molecular target: Epidermal growth factor variant III (EGFRvIII) Description: Vaccine …

    Published on 11/24/2014
  • Rucaparib: Phase II data

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Pfizer Inc. (NYSE:PFE), New York, N.ZZZ. Cancer Research UK, London, U.K. Product: Rucaparib (CO-338) (formerly PF-01367338, AG-014699) Business: Cancer Molecular …

    Published on 11/24/2014
  • scAAV2/8-LP1-hFIXco: Phase I data

    The Royal Free Hospital, London, U.K. St. Jude Childrens Research Hospital, Memphis, Tenn. University College London, London, U.K. Product: scAAV2/8-LP1-hFIXco Business: Hematology Molecular target: Factor IX …

    Published on 11/24/2014
  • Selinexor: Additional Phase I data

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 11/24/2014
  • Tafinlar dabrafenib: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Tafinlar dabrafenib (GSK2118436) Business: Cancer Molecular target: BRAF Description: Oral BRAF protein kinase inhibitor Indication: Treat unresectable or …

    Published on 11/24/2014
  • Tivantinib: Phase II data

    ArQule Inc. (NASDAQ:ARQL), Woburn, Mass. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Tivantinib (ARQ 197) Business: Cancer Molecular target: c-Met …

    Published on 11/24/2014
  • VAX2012Q: Phase I data

    VaxInnate Corp., Cranbury, N.J. Product: VAX2012Q Business: Infectious Molecular target: NA Description: Recombinant quadrivalent hemagglutinin seasonal influenza vaccine Indication: Prevent seasonal influenza infection…

    Published on 11/24/2014
  • Vytorin ezetimibe/simvastatin: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Vytorin ezetimibe/simvastatin Business: Cardiovascular Molecular target: HMG-CoA reductase Description: Cholesterol absorption inhibitor plus HMG-CoA …

    Published on 11/24/2014
  • ABT-450 plus ritonavir/ombitasvir: Phase II data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-450 plus ritonavir/ombitasvir (ABT-267)/dasabuvir (ABT-333) (3 direct-acting-antiviral (3D) regimen) …

    Published on 11/17/2014
  • ABT-450 plus ritonavir/ombitasvir: Phase IIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-450 plus ritonavir/ombitasvir (ABT-267) Business: Infectious Molecular target: HCV NS3/4A protease complex;…

    Published on 11/17/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993